Related Experiment Video

Updated: Dec 19, 2025

Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography
09:34

Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography

Published on: February 17, 2022

3.7K

Tocilizumab in the treatment of a critical COVID-19 patient: a case report

L Wang1, X Peng, Z-H Wang

  • 1Department of Neurology, the First Affiliated Hospital of Chongqing Medical University, Chongqing, China. zfc88@126.com.

European Review for Medical and Pharmacological Sciences
|June 5, 2020
PubMed

Insights

Tocilizumab effectively treated a critical COVID-19 patient experiencing a cytokine storm. This interleukin-6 receptor blocker shows promise for severe cases of the ongoing pandemic.

Area of Science:

  • Immunology
  • Virology
  • Clinical Medicine

Background:

  • The COVID-19 pandemic, caused by SARS-CoV-2, presents a significant global health challenge.
  • Severe COVID-19 cases are often characterized by a detrimental "cytokine storm."
  • Interleukin-6 (IL-6) is a key mediator implicated in the pathogenesis of the cytokine storm.

Observation:

  • A critical COVID-19 patient presented with severe symptoms indicative of a cytokine storm.
  • The patient's condition necessitated aggressive therapeutic intervention.

Findings:

  • Tocilizumab, an interleukin-6 receptor antagonist, was administered to the critical patient.
  • The administration of tocilizumab resulted in a positive clinical response, indicating its efficacy.

Implications:

  • Tocilizumab represents a potential therapeutic option for managing severe COVID-19 patients.
  • Targeting the IL-6 pathway may be a viable strategy to mitigate the effects of cytokine storms in viral infections.
  • This case report contributes to the growing body of evidence supporting immunomodulatory therapies in critical COVID-19 care.

More Related Videos

Author Spotlight: Advancing Pathogen Detection and Disease Assessment in Real-Time Using M-ROSE03:22

Author Spotlight: Advancing Pathogen Detection and Disease Assessment in Real-Time Using M-ROSE

Published on: March 1, 2024

769
Halogenated Agent Delivery in Porcine Model of Acute Respiratory Distress Syndrome via an Intensive Care Unit Type Device09:36

Halogenated Agent Delivery in Porcine Model of Acute Respiratory Distress Syndrome via an Intensive Care Unit Type Device

Published on: September 24, 2020

3.0K

Related Concept Videos

Chronic Obstructive Pulmonary Disease-V: Management01:29

Chronic Obstructive Pulmonary Disease-V: Management

Managing Chronic Obstructive Pulmonary Disease (COPD) involves a multifaceted approach to reduce symptoms, prevent exacerbations, improve overall health status, and slow disease progression. Key strategies include lifestyle modifications, pharmacotherapy, supportive therapies, and, in some cases, surgery. Here is an overview of the primary COPD management strategies:
Smoking Cessation
3.0K
Pneumonia IV: Management01:28

Pneumonia IV: Management

The treatment of pneumonia varies based on its severity and the causative pathogen. Here is a structured approach to managing pneumonia, integrating pharmaceutical and supportive care strategies.
Bacterial Pneumonia Treatment
For bacterial pneumonia, antibiotics serve as the cornerstone of therapy. Initial treatment often begins with empirical antibiotics, tailored to the anticipated causative organism and adjusted based on culture results. Key antibiotic choices include:
662
COPD: Management Using Bronchodilators and Corticosteroids01:26

COPD: Management Using Bronchodilators and Corticosteroids

Chronic obstructive pulmonary isease (COPD) involves a group of progressive lung disorders characterized by persistent airflow limitation and chronic respiratory symptoms. Asthma-COPD Overlap Syndrome (ACOS), encompassing features of both asthma and Chronic obstructive pulmonary disease (COPD), is a group of progressive lung disorders that includes chronic bronchitis, emphysema, and refractory (non-reversible) asthma. ACOS leads to complex clinical presentations that combine the inflammatory...
630
Cystic Fibrosis: Management01:24

Cystic Fibrosis: Management

Cystic fibrosis (CF) is an autosomal recessive disorder that predominantly affects individuals of Northern European descent, occurring at a rate of 1 in 3500. It is caused by a genetic mutation in a gene on chromosome 7, most commonly the ΔF508 mutation, that codes for the cystic fibrosis transmembrane conductance regulator (CFTR) protein. This results in thicker mucus secretions and obstruction pathologies in multiple organs, including the lungs and sinuses.
Sinus disease and chronic...
362
Chronic Pancreatitis II: Collaborative Care01:29

Chronic Pancreatitis II: Collaborative Care

The management of chronic pancreatitis is multifaceted, involving a comprehensive approach that includes thorough assessment, diagnostic testing, and a variety of management strategies.
Assessment:
216
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents01:29

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
379